Eikan Mishima Kazuichi Maruyama Toru Nakazawa Takaaki Abe Sadayoshi Ito
10.2169/internalmedicine.56.8313
Intern Med
2017;56(13):1687-1690.
cyp3a4 acute kidney injury calcium-channel blockers drug interaction hypertension nifedipine
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/28674358/
Acute Kidney Injury / chemically induced Calcium Channel Blockers / adverse effects Clarithromycin / pharmacology Cytochrome P-450 CYP3A Inhibitors / pharmacology Nifedipine / adverse effects Voriconazole / pharmacology
Acute Kidney Injury / chemically induced Calcium Channel Blockers / adverse effects Clarithromycin / pharmacology Cytochrome P-450 CYP3A Inhibitors / pharmacology Nifedipine / adverse effects Voriconazole / pharmacology Case Reports Aged Anti-Bacterial Agents / therapeutic use Blood Pressure / drug effects Calcium Channel Blockers / therapeutic use Clarithromycin / therapeutic use Cytochrome P-450 CYP3A Inhibitors / therapeutic use Drug Synergism Humans Hypertension / drug therapy Hypotension / chemically induced Male Nifedipine / pharmacology Nifedipine / therapeutic use Voriconazole / therapeutic use Anti-Bacterial Agents Calcium Channel Blockers Cytochrome P-450 CYP3A Inhibitors Clarithromycin Nifedipine Voriconazole
PMC5519471
28674358
Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole
2017